This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markman, M. Articles by Baker, M. Search for Related Content PubMed PubMed Citation Articles by Markman, M. Articles by Baker, M. Social Bookmarking                            What's this?

Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

PURPOSE: We wished to critically examine the level of activity of weekly paclitaxel in a patient population with well-characterized platinum/paclitaxel-resistant (3-week schedule) ovarian cancer.

PATIENTS AND METHODS: Eligibility criteria for this phase II trial included the following: ovarian and fallopian tube cancers or primary carcinoma of the peritoneum; prior initial therapy with platinum/paclitaxel; and failure to respond to treatment (progression or stable disease as best response), or a response duration of less than 3 months, or if the response was more than 3 months, retreatment with both agents required and failure to respond a second time or the response duration was less than 3 months. Measurable or assessable disease (CA-125 response criteria) was required. Patients received weekly paclitaxel (80 mg/m²) until disease progression, unacceptable toxicity developed, or they elected to discontinue treatment.

RESULTS: Fifty-three patients (52 assessable for toxicity and 51 for response) were entered onto this multi-institution trial. Of 248 total cycles (887 doses), only 13 (1%) were modified (dose reduction or treatment delay) because of side effects. Therapy was discontinued in five patients because of toxicity (four because of peripheral neuropathy, and one because of painful fingernail beds). Thirteen patients (25%; 95% confidence interval, 13.5% to 37.5%) achieved an objective response (four by CA-125 criteria, and nine by 50% reduction of measurable disease).

CONCLUSION: Weekly paclitaxel (80 mg/m²) is generally well tolerated and is an active second-line regimen against ovarian cancer that has demonstrated resistance to platinum/paclitaxel delivered on an every-3-week schedule.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, and D. Wang Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 237 - 243. [Abstract] [Full Text] [PDF]

				N. Penel, B. N. Bui, J.-O. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez, et al. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study J. Clin. Oncol., November 10, 2008; 26(32): 5269 - 5274. [Abstract] [Full Text] [PDF]

				M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]

				A. A. Kamat, T. J. Kim, C. N. Landen Jr., C. Lu, L. Y. Han, Y. G. Lin, W. M. Merritt, P. H. Thaker, D. M. Gershenson, F. Z. Bischoff, et al. Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer Cancer Res., January 1, 2007; 67(1): 281 - 288. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529. [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				V. Hess, M. W. Verrill, C. C. Bomphray, M. M. Vaughan, M. Allen, and M. E. Gore Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma Ann. Onc., April 1, 2003; 14(4): 638 - 642. [Abstract] [Full Text] [PDF]